Brind.
  1. Novo Nordisk and MetaVia, Inc. developed dual GLP-1/glucagon receptor agonists.

MTVA's novel GPR119 agonist, DA-1241, is being developed in collaboration to expand its therapeutic potential.

2 reports, 1 independent Updated Aug 4
Gone quiet
Reports
2
Developments
2
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

MTVA's novel GPR119 agonist, DA-1241, is being developed in collaboration to expand its therapeutic potential.

Who's involved

What this event is mainly about
MTVA

How it developed

Newest first. Tap a step to see who reported it.
  1. Collaboration announced to expand the therapeutic potential of MTVA's GPR119 agonist, DA-1241.1 source
  2. MetaVia preclinical data shows DA-1241 and efruxifermin successfully treat MASH models.

Keep exploring

Part of

Novo Nordisk and MetaVia, Inc. developed dual GLP-1/glucagon receptor agonists. All 1 developments

The entities involved

  • MTVA

    Hungarian record label

    Nothing else this week.

Coverage

Newest first; wire copies grouped
  • PR NewswireMetaVia Announces AI-Driven Collaboration with Syntekabio to Explore Additional Indications for DA-1241 Partnership Leverages Syntekabio's DeepMatcher® Platform to Expand the Therapeutic Potential of
  • Unknown outlet